about
Review of periprosthetic osteolysis in total joint arthroplasty: an emphasis on host factors and future directionsTargeting dendritic cell function during systemic autoimmunity to restore toleranceNovel targeted therapeutics for metastatic castration-resistant prostate cancer.Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.Prostate cancer and bone: the elective affinities.Local application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit modelSafety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence.Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.The emerging field of osteoimmunologyBone health in nonmetastatic prostate cancer: what's the big deal?Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw.Treatment and prevention of bone complications from prostate cancer.High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutationTargeted therapy in prostate cancer.Contemporary therapeutic approaches targeting bone complications in prostate cancerInnovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis.Effect of bisphosphonates on orthodontic tooth movement-an updateGlucocorticoid use in acute lymphoblastic leukaemiaMouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow.Current and emerging therapies for the treatment of osteoporosisIntegrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients.Painful boney metastases.Cervical actinomycosis with spinal cord compression. Case report and literature review.Current state and future of joint replacements in the hip and knee.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Emerging treatments for postmenopausal osteoporosis - focus on denosumab.Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.Role of denosumab in breast cancer.Emerging therapeutic targets in breast cancer bone metastasis.Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.Androgen deprivation and bone.Therapeutic targeting of osteoclast function and pathways.A multi-targeted approach to treating bone metastases.Osteoprotegerin and kidney disease.Novel agents in the management of castration resistant prostate cancer.New management options for osteoporosis with emphasis on SERMs.Osteocytic signalling pathways as therapeutic targets for bone fragility.Hormonal Modulation of Dendritic Cells Differentiation, Maturation and Function: Implications for the Initiation and Progress of Systemic Autoimmunity.
P2860
Q27009529-FA69A9EE-F545-411F-B3C0-C5C481D5C7A7Q27687098-BAAB72ED-36DD-401B-B645-506C54BB5FDBQ33642278-44F7AFAD-AC8D-4EAD-8095-992C6544ED36Q33754036-70CCD8BB-DB28-4CB7-AA14-7E8B303AC805Q33757791-5BB18A02-BEAA-4409-84C4-10B16656B60AQ33862655-4C266CD7-0361-4B7E-AB1A-9A85A4406591Q33900327-1F661B63-9C30-4C24-A325-2D68081E8815Q33953955-91136923-917D-49FE-B7CC-B62E0D8DADECQ34108110-5A36425C-66CF-4BA5-91C8-6FD2C4C8A521Q34111621-EE635F70-C3BA-4FBD-BFBE-93507DFE6BB3Q34162783-AB8C1614-6E90-4F1D-94AA-A12A0A468D93Q34441944-726D7B5A-DEF2-45DC-A5F7-71D82F2F3A51Q34482369-9746E59C-F936-45FB-B471-4DF7ADE788C6Q34634763-0E53695C-2B77-4CF9-9F03-3D69F7A0496EQ34960778-4A0CD2F2-97B3-48A4-BCB0-145B8A4B8A11Q34991655-21B140EC-1831-46EF-9F8C-878FBF55AD73Q35003674-167C4D27-E846-493F-8E9E-3C60371179B0Q35310572-710BD0F4-8B1F-48B8-8D60-F7419DD133DAQ35622970-A7A2F234-81C1-43A6-B4C6-04F1F12A740EQ35844745-F0AE3EBF-2C59-4C4C-88A4-4C8080955FB3Q36823728-D9EE325A-6F8C-4314-BC8E-D297ED08D560Q36890431-D13DFCDB-5955-4821-A210-D9F89F7214DEQ36952052-CF59076D-A2C1-4B4E-AC0E-AF019A74DAD2Q37011060-9AF6B63F-6E38-41FA-92D0-03A4DFC38C81Q37029680-56CC5756-69B7-43EA-B119-C6637135C0CEQ37152851-407BE8F9-BCD7-4743-AD8D-FB5BA1DF3A7DQ37187646-47A93A97-B018-46BB-8EA6-57114BF4AE9CQ37230477-825E2B0A-7A72-480C-A6D2-7399143503C9Q37342578-0B84D8F1-BF6E-45ED-AE6A-8D140AF3C240Q37571986-EE40CC3B-AC58-40BE-B1CD-101399A37CF4Q37658767-E5CDEA93-FB56-46B9-AEB5-F967360F44E0Q37720488-B161DAE5-B9B8-49BB-8259-EE603027DB0FQ37821350-0570F1D4-345E-40A3-A4EE-6FEAB2C5720BQ37825905-E99A264A-EB1C-4ADA-92E3-BB4ABA80B55FQ38175846-6C7FA5EB-02A2-4D06-A9E1-1B46AB29DDF8Q38206487-19C51A91-E7FB-401D-B1CF-5667DF1E4B2EQ38209656-5EB05213-0EAB-4A78-9DE8-3D9C0B32B645Q38616755-A2F55BC9-4A36-49F2-ADDA-38DD6D69622DQ38845640-CC9EDAD3-670C-4DE0-BB78-A5C4B67D89A2Q38944092-E000A0E7-3216-47D9-A97C-E0E6F700FF2E
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Clinical development of anti-RANKL therapy
@ast
Clinical development of anti-RANKL therapy
@en
type
label
Clinical development of anti-RANKL therapy
@ast
Clinical development of anti-RANKL therapy
@en
prefLabel
Clinical development of anti-RANKL therapy
@ast
Clinical development of anti-RANKL therapy
@en
P2860
P356
P1476
Clinical development of anti-RANKL therapy
@en
P2093
Edward M Schwarz
P2860
P2888
P356
10.1186/AR2171
P478
P577
2007-01-01T00:00:00Z
P5875
P6179
1020038270